Login
Companies $LEGN
$16.22 +$0.23 (1.41%) After hours
Legend Biotech Corp logo

Legend Biotech Corp

legendbiotech.com

What Do They Do?

Develops and commercializes cell therapies for people with cancer, including CARVYKTI for multiple myeloma, while developing additional therapies for cancer and autoimmune conditions.

How Do They Make Money?

Legend earns a share of CARVYKTI sales with Janssen when Janssen sells and delivers the product outside Greater China. It also licenses cell therapies to Novartis for upfront and milestone payments and royalties.

FY2025 revenue

Who Are Their Customers?

CARVYKTI customers buy from Janssen outside Greater China and from Legend in Greater China.

How Are They Changing?

Growing. Revenue grew 14.9x in 4 years, from $68.8M in FY2021 to $1B in FY2025, about 97% a year.

Commercialization The earlier report described Legend as primarily clinical-stage while noting CARVYKTI's launch; the latest describes an established sales, marketing and operating infrastructure.

Broader cell therapy pipeline The earlier report described autologous CAR-T candidates and an allogeneic CAR-T candidate; the latest also lists CAR-NK, in-vivo CAR-T and autoimmune programs.

Manufacturing facilities The earlier report said it was building manufacturing facilities in the United States, EU and China; the latest says it has facilities in the United States and Belgium for commercial supply.

Who Do They Compete With?

Competes with Novartis, Kite, Bristol-Myers Squibb, bluebird bio, Arcellx, Autolus Therapeutics, Johnson & Johnson, Caribou Biosciences, CARsgen Therapeutics, AstraZeneca, IASO Biotechnology, Oricell Therapeutics, Roche, Kelonia, EsoBiotech, Interius, Amgen, Regeneron Pharmaceuticals, GSK, and Innovent

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support